Corporate Presentation

Obesity Dapiglutide In H1 2024, results for dapiglutide are expected from the investigator-led DREAM trial ZEAL& ZEALAND PHARMA DREAM is evaluating the effects of dapiglutide on body weight, gut permeability, and inflammation¹ ÅÅÅ Population N=54, men and women aged 18–75 y BMI ≥30 kg/m² years Duration 12 weeks Dose strengths Endpoints Similar to the doses evaluated in the previous 4-week MAD trial, thus up to 6.0 mg² Primary endpoint: percentage change in body weight from baseline to Week 12 Key secondary endpoints: patients with a body weight reduction ≥5% and ≥10%; percentage change in fasting serum/plasma concentrations of biomarkers for gut permeability and inflammation Sources: 1. ClinicalTrials.gov (NCT05788601), accessed November 2023; 2. Data presented by Agersnap at the 82nd ADA Scientific Sessions, June 3-7, 2022, New Orleans, LA. BMI-body mass index; MAD=multiple ascending dose. 22 22

View entire presentation